Background: Ubiquinol is widely used as an anti-aging supplement. In this study, we evaluated
form (ubiquinone). The one that has efficacious bioactivity in the body is ubiquinol [21] . When ubiquinone is ingested through daily food intake, it is converted into ubiquinol by NADPH-dependent ubiquinone reductase. Therefore, ubiquinol is likely a more effective dietary supplement than ubiquinone due to its direct bioactivity. Recent studies have reported that ubiquinol supplementation increases plasma CoQ10 levels for CHF patients [22] and decelerates the senescence in senescence-accelerated mice [23] , while significant effects using ubiquinone have not been shown.
However, few clinical trials evaluating the effects of ubiquinol on maintaining or enhancing the health of non-diseased individuals have been conducted. One previous study using a test group of healthy elderly participants demonstrated the potential effect of ubiquinol on their mental health, but the sample group was small, and the study itself did not examine blood ubiquinol levels [20] . Further investigation on the effects of ubiquinol intake on healthy populations is therefore required.
In the present study, we conducted a clinical trial to evaluate the effects of long-term intake of ubiquinol on improving or maintaining the QOL of community residents in a "super-aging" region in Japan. This prospective trial has the potential to contribute to the health of elderly residents in general
METHODS

Participants
Ubiquinol Health Examination is an ongoing prospective intervention trial that started in November 2013. The participants are volunteers residing in Kamijima town, Ehime Prefecture.
Kamijima is located approximately 700 km west of Tokyo in the Seto Inland Sea. Kamijima is a "super-aging" region with a population aging rate of 37.7 % according to the 2010 census. It was selected in this study to evaluate the effects of anti-aging supplements. The selection criteria of the participants were that they had to be 20 years of age or older and to have given their written informed consent prior to participation. The exclusion criteria were as follows: pregnant women, women who were breast-feeding, and others judged as unfit to participate by a physician or study director. In total, the study included 124 participants (male=36, female=88, aged 22-86 years) who were enrolled in November 2013 (n=102) and in May 2014 (n=22) (Figure 1 ). This study was approved by the Institutional Review Board of Ehime University Hospital (authorization number 1309018). Written informed consent was obtained from all participants.
Figure 1. Outline of Ubiquinol Health Examination
Study design
We conducted this study by an open-label single-arm design. Participants consumed a supplement containing 100-120 mg of ubiquinol per day for either 6 or 12 months from the day they agreed to participate in the Ubiquinol Health Examination (Figure 1 ). Outcomes were measured at baseline and after the long-term intake of ubiquinol supplements. Since Ikematsu et al. reported that significant changes in plasma CoQ10 concentration had not been shown during 6 weeks in placebo intake group [24] , we did not employ run-in period in this study. Participants were directed not to change their lifestyles during this trial. We confirmed that the lifestyle of participants had not changed substantially every 6 months using a questionnaire.
Ubiquinol supplementation
We prepared two types of ubiquinol supplements: granule and soft capsule, each of which contained 100-120 mg of ubiquinol (Kaneka Corporation, Osaka, Japan). Participants were given their preferred choice of format. We examined non-fasting blood tests, serum ubiquinol levels, plasma homocysteine, and serum pentosidine as markers of bone quality. [27] . Scores of each scale range from 0 to 100, with higher scores representing better QOL. We examined fatigue level, as the activation of mitochondrial energy production by ubiquinol would affect the fatigued states of participants [28] . Fatigue level was measured by stress level from the ratio of low frequency (LF) to high frequency (HF), the total power (TP) of autonomic function, and the coefficient of component variance total power (ccvtp). For examination, participants were asked to sit for two minutes at rest while holding a "Vital Monitor"
device (Hitachi Systems, Ltd., Tokyo, Japan) in their hands.
Statistical analysis
We analyzed the changes in variables and correlations between the change in ubiquinol level and the changes in variables. For the analysis of changes, we used Wilcoxon signed-rank tests. For the analysis of correlation, we used Spearman's rank-correlation coefficient. We further analyzed the changes in SF-36 scores after stratifying the tertiles of baseline serum ubiquinol levels.
Results with P<0.05 in the two-sided tests were considered statistically significant. All statistical analyses were performed with SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA Table 1 shows the baseline characteristics of the participants. Serum ubiquinol levels were significantly higher in male participants than in females. With respect to SF-36 subscales, the scores of PF, RP, VT, and RE of males were significantly higher than those of females.
RESULTS
Homocysteine of males was significantly higher than that of females. Other variables showed no significant differences between sexes. Figure 2 shows the serum ubiquinol level of individuals at baseline and after the long-term intake of ubiquinol. Mean serum ubiquinol levels increased significantly after long-term intake (from 1.05 to 4.25 µg/ml, P<0.01). Table 2 shows the measurements at baseline and after long-term intake, as well as their changes for both male and female participants. In males, SF-36 scores did not show significant changes, while in females, the scores of RE, VT, SF, MH, and MCS increased significantly. Regarding fatigue level, significant improvement was not demonstrated in either sex. With respect to plasma homocysteine and serum pentosidine, no significant changes were found in males, while in females, plasma homocysteine increased significantly (from 9.4 to 9.6 nmol/ml, P<0.01). Table 2 Measurements at baseline and after long-term intake, and the changes in variables.
Values are expressed as mean ± standard deviation.
Wilcoxon signed-rank test. Table 3 shows the correlation coefficients between the change in serum ubiquinol level and the change in SF-36 scores. In both sexes, significant correlations were not found. Table 4 shows the changes in SF-36 scores after stratifying baseline serum ubiquinol levels by tertile. In the low ubiquinol level group of female participants, the scores of VT and MCS improved significantly, whereas the scores of PF and MCS decreased significantly. In the middle ubiquinol level group of female participants, the scores of PF, RP, VT, SF, and MH improved significantly. Meanwhile in males, SF-36 scores did not show significant changes in any tertile. improvement, especially their psychological QOL. To evaluate the psychological QOL, the questionnaires relating to vitality and mental condition were used, for instance "Did you feel full of pep?" "Have you been a very nervous person?"
Ubiquinol is known to play a key role in mitochondrial energy production [2] , and administering ubiquinol has previously been tested as a way to enhance vitality or reduce fatigue in hospital-based studies [15] [16] [17] [29] [30] . In addition, SF-36 scores have shown a significance or tendency for improvement in the clinical trials of L-carnitine [31] [32] , which is considered to function in the tricarboxylic acid cycle as a producer of mitochondrial energy like ubiquinol [33] [34] . Another well-known key role of ubiquinol is its antioxidant effect [4] [5] . In this study,
we observed significant increment of serum ubquinol levels after long term intervention. A review [2] indicated that since a majority of the coenzyme Q in cell membranes was in the quinol form, it could be a very effective antioxidant. The absolute amount of ubiquinol level in serum could reflect the amount of the coenzyme Q in cell membranes Therefore, we thought that the increment of serum ubiquinol levels may surrogate well antioxidant effects for our subjects. A previous study using animals reported that dietary supplementation with CoQ10 reduced brain oxidative stress and improved the psychological condition of the test subjects [35] . It was suggested that ubiquinol activates the mitochondrial energy production cycle and antioxidant effects, leading to improvement in the QOL of females.
Contrary to previous studies such as the trials for CHF [23, [35] [36] [37] , chronic fatigue syndrome [28] , and Parkinson's disease [13, 38] , in the present study, the participants were primarily a healthy population. Therefore, mean levels of serum ubiquinol in the present participants would typically be higher than those of less healthy patients. It should be noted that the daily dose tested in the present study was administered at the same level as commonly-used in over-the-counter doses (100-120 mg/day), since the participants were healthy overall. In hospital-based studies, significantly high doses (1200-2400 mg/day) of CoQ10 have been administered [28, 38] . In the present study using healthy residents, we were able to demonstrate the effects of commonly-used dosages of ubiquinol intake on females' QOL, especially for those whose serum ubiquinol levels were at a lower or middle range.
Regarding the lack of significant improvement in the QOL of male participants, we suggest a few possible reasons. First, males had high baseline scores of SF-36 compared to females to begin with. Even in females, significant improvements of QOL scores were not seen in the highest baseline tertile. In male participants, though 10 of 11 SF-36 scores for males trended lower, every subscale score after ubiquinol intake indicated around 50, those were standard levels. We consider that those were non-substantial changes within normal ranges. Second, males had higher baseline serum ubiquinol levels than females. This is probably due to the amount amount of daily foods sources for coenzyme Q10 intakes, i.e. meats and fishes. Therefore, the increment of ubiquinol levels could not contribute on male's QOL. Additionally, it is quite possible that in males, QOL scores were more affected by residual confounding factors, which
were not examined in this study, rather than by serum ubiquinol levels.
Significant correlations between a change in serum ubiquinol level and a change in SF-36 scores were not shown in either sex. While the serum ubiquinol level increased significantly, and several of the SF-36 scores improved significantly in female participants, no significant correlation was observed between the change in ubiquinol level and the changes in SF-36 scores.
However, this does not mean that the more serum ubiquinol levels increase, the more QOL scores improve. It is possible that serum ubiquinol levels have an optimal threshold, after which point any increase in the level would not lead to further improvement in QOL.
With respect to fatigue level, we failed to demonstrate a significant improvement, although
we had an a priori hypothesis that activating energy production by ubiquinol should affect autonomic TP. These results could be due to the strong correlation between TP and aging (internal data). Since this study was a long-term trial, it is suggested that the effects of aging were stronger than the effects of ubiquinol intake.
During this long-term trial, we saw no serious side effects caused by ubiquinol. As shown in Table 2 , homocysteine increased significantly in females (from 9.4 to 9.6 nmol/ml). However, this increase was within normal range and could even be due to advancing age, given the fairly long intake periods of this study. In any case, continued follow-up is needed throughout this ongoing trial.
One of the strengths of our study is that it is the first large-scale and long-term trial among community residents to evaluate the effects of ubiquinol on QOL improvement. Most previous studies on CoQ10 have evaluated its effects on patients with pre-existing illnesses. We also showed the effects of ubiquinol on the QOL improvement of female participants with relatively low serum ubiquinol levels.
With regard to limitations, we first acknowledge that since this study was an open-labeled and single-arm trial, the findings might have included some placebo or period effects. However, the improvements of QOL were found only in female participants and mainly in the mental status scores. If the placebo or period effects were strong, the improvement should have been found in male participants as well as in the physical status scores. Second, we found effects only on subjective QOL, and not on objective variables such as fatigue level and blood examination.
However, SF-36 has already been validated and used in many studies, even though it is a subjective questionnaire. For instance, the antioxidant effect of ubiquinol is known to complement the antioxidant activity of Vitamin E [39] [40] , and in the clinical trials of Vitamin E supplementation, SF-36 subscales have been used for evaluation [41] [42] .
With the population aging rapidly, many developed countries are now facing social problems related to their health insurance systems and medical costs. In these circumstances, the general public and communities are required to take charge of their own healthcare activities as a way of reducing medical spending, especially in terms of their healthy life-span. Clinical trials among healthy populations, such as the study reported here, will increase in importance in the years to come as new strategies for the prevention of diseases.
CONCLUSIONS
In our study, we discovered evidence demonstrating significant effects of ubiquinol on the mental condition of female participants. We will continue the follow-up with the test population, with the enrollment of additional participants and investigation of other anticipated effects of ubiquinol, including the functioning of mitochondrial energy production and antioxidant activity. Author's contributions: All authors contributed to this study.
